Merck Sharp & Dohme (MSD) recently reported that a combination of two drugs showed promising results in suppressing HIV-1 replication during two late-stage clinical trials.
MSD seeks new growth drivers to offset the potential hit if its blockbuster cancer immunotherapy Keytruda loses patent protection.
MSD’s clinical trial, involving over 1,000 patients, evaluates the efficacy of combining Doravirine and Islatravir.
One study revealed that MSD’s combination therapy demonstrated a better safety profile compared to Gilead’s HIV drug, Biktarvy. However, in patients already receiving Gilead’s medication, the new treatment didn’t surpass Biktarvy’s effectiveness in suppressing HIV-1, the most prevalent HIV strain.
Meanwhile, MSD intends to submit the clinical trial data to regulatory authorities and present detailed findings at an upcoming conference.
Most Commented